^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    LucenceINSIGHT™

    Company:
    Lucence
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    3ms
    Lucence and Diagnostics Development Hub (DxD Hub) collaborate on expanding multi-cancer early detection testing to alternative sample types (Lucence Press Release)
    "Lucence and the Diagnostics Development Hub (DxD Hub)...are collaborating to develop and pivot the use of Lucence’s multi-cancer early detection test (LucenceINSIGHT™) on alternative sample types. This collaboration represents a significant advancement in our efforts to make cancer screening more accessible to patients. We will also be partnering with local hospitals to identify and recruit eligible patients for this study. This collaborative effort aims to enhance the reach and impact of our research by leveraging the expertise and resources of our esteemed healthcare partners."
    Licensing / partnership
    |
    LucenceINSIGHT™
    1year
    Initial experience in a real-world Asian cohort with a circulating tumor DNA (ctDNA) mutation-based multi-cancer early detection (MCED) assay (ESMO Asia 2023)
    A majority of cases detected were not covered under traditional screening guidelines. These findings provide additional support for the use of ultrasensitive mutation-based assays for screening.
    Real-world evidence • Clinical • Circulating tumor DNA • Real-world
    |
    LucenceINSIGHT™
    over1year
    Lucence launches LucenceINSIGHT to detect cancer earlier (Lucence Press Release)
    "Lucence unveiled LucenceINSIGHT™, its pioneering multi-cancer early detection (MCED) blood test, at their US headquarters...Lucence is launching LucenceINSIGHT™, an MCED test first internationally and with a follow-up U.S. launch in Q3 2023. This ctDNA-based liquid biopsy test screens for 10 common cancers in one blood draw."
    Launch
    |
    LucenceINSIGHT™